Pay in 4 interest-free payments of $7.40 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Common Side Effects When side effects occurred, they were typically mild, transient, and similar in frequency to placebo groups: Reported Adverse Effects Most Common (occurring in small percentage of participants): Mild to moderate headaches (most frequently reported, often resolving with continued use) Injection site reactions (minor redness, swelling, or irritation at injection site) Gastrointestinal effects (particularly at higher oral doses: mild nausea, diarrhea, flatulence) Fatigue (reported occasionally during initial adaptation period) Rare Events: One case of chest tightness was deemed possibly related to treatment in safety trials
has operated since 1988 - over 36 years as of 2026
Contact your doctor immediately if you experience: Severe, persistent abdominal pain that may indicate pancreatitis, particularly if radiating to the back or accompanied by vomiting Signs of gallbladder disease , including right upper quadrant pain, fever, jaundice, or clay-colored stools (cholelithiasis rates in clinical trials range from approximately 0.6% to 2.5%, depending on dose and duration) Symptoms of acute kidney injury , such as decreased urination, swelling, fatigue, or confusion, especially if accompanied by dehydration Visual changes , including blurred vision or difficulty focusing, which may indicate diabetic retinopathy complications (rapid glycemic improvement with tirzepatide can temporarily worsen retinopathy) Severe allergic reactions , including rash, itching, swelling of face or throat, severe dizziness, or difficulty breathing Persistent vomiting or diarrhea lasting more than 24 hours, which increases dehydration and acute kidney injury risk Symptoms suggesting thyroid tumors , including neck mass, hoarseness, dysphagia, or dyspnea New or worsening depression, suicidal thoughts, or unusual changes in mood or behavior , particularly in patients taking Zepbound for weight management Routine monitoring should include periodic assessment of renal function, particularly in patients with pre-existing kidney disease or those experiencing significant gastrointestinal symptoms
Consult your healthcare provider If hunger persists despite nutritional and lifestyle adjustments, a medical review is appropriate
Researchers studying metabolic syndrome, NAFLD, and obesity have noted these downstream effects as particularly significant for the differentiation between the two compounds
The ED-A domain of fibronectin and vitronectin-integrin interactions collectively enhance TGF responsiveness and reinforce a pro-fibrotic microenvironment (260)
